Akebia Therapeutics, Inc. AKBA
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a cardio-renal-metabolic drug developer. Its lead program, Vafseo (vadadustat), is in Phase 2 for Anemia due to CKD (dialysis).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Vafseo (vadadustat) | Anemia due to CKD | small molecule | Approved |
| praliciguat | FSGS | small molecule | Phase 2 |
| ebribafusp (AKB-097) | IgAN/C3G/lupus nephritis | protein/peptide | Phase 2 |
| AKB-9090 | Cardiac surgery-related AKI | small molecule | Phase 1 |
| AKB-10108 | HIF | small molecule | Pre-clinical |
Recent results and decisions
- Oct 21, 2026n/a Akebia receives Nasdaq deficiency notice for failing to maintain minimum bid price of $1.00 per share for 30 consecutive business days, with compliance deadline of April 19, 2027.
The Company has an initial period of 180 calendar days, or until April 19, 2027 (the 'Initial Compliance Period'), to regain compliance with the Bid Price Requirement.
Filing - Jun 30, 2026met VOICE (n=2,116) stopped early at interim after meeting non-inferiority and superiority on the mortality/hospitalization composite, win odds 1.16 (95% CI 1.06-1.28, p=0.0016), with fewer hospitalizations and no mortality difference.
demonstrated that the trial met the predefined stopping criteria with a win odds of 1.16 (95% confidence interval ("CI") 1.06, 1.28, p=0.0016), establishing non-inferiority and superiority of the primary composite endpoint
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.